Background: Approximately one-third of refugees worldwide live in refugee camps. Selected neurologic diseases are actively reported in some refugee camps.
collected at each camp by UNHCR employees and other aid workers on a weekly basis, involving 25 implementing organizations worldwide, using case definitions (table 1) . Approximately 1.6 million displaced persons are covered by camps participating in the webHIS. Visit data are collected via a standardized online reporting form, downloaded at the refugee camp site, and deposited electronically each month. Not all refugee camps report on all reportable neurologic diseases every month. For each month, the number of camps reporting on the disease of interest was calculated. The tallies were then summed over months and used to standardize the reporting counts of specific diseases, yielding per camp-month visit rates. This standardization allowed counts to be compared across various strata (e.g., sex, reporting years).
For each health visit, patient sex, location, and month of encounter were reported. Neurologic diseases were searched among all reportable diseases in webHIS during the study timeframe (January 1, 2008 -December 31, 2011 for acute flaccid paralysis, leprosy, and meningitis; July 1, 2009 -December 31, 2011 for cerebrovascular disease and epilepsy). Camp level information is available at https://unhcr.org/his. Use of deidentified programmatic data used in this study was approved by The Johns Hopkins University Institutional Review Board.
RESULTS

Participating countries were from 3
World Health Organization-defined regions: African (93 refugee camps in 13 countries: Burundi, Cameroon, Central African Republic, Chad, Democratic Republic of Congo, Ethiopia, Guinea, Kenya, Namibia, Rwanda, Tanzania, Uganda, Zambia), Eastern Mediterranean (14 refugee camps in 3 countries: Djibouti, Sudan, Yemen), and Southeast Asian (20 camps in 3 countries: Bangladesh, Nepal, Thailand). The countries with the highest number of reporting camps were Chad (n ϭ 28), Ethiopia (n ϭ 13), Uganda (n ϭ 11), Sudan (n ϭ 10), and Cameroon (n ϭ 10). Reporting of epilepsy and cerebrovascular disease began in July 2009 and was available in 14 countries for cerebrovascular diseases and 16 countries for epilepsy (table 2) .
There were 5 reported neurologic diseases in the webHIS of the UNHCR. In 2011, these diseases accounted for 31,349 visits globally of which 91% were for epilepsy. The age distribution of the 53,941 health visits for epilepsy for all years reported was as follows: Ͻ5 years old (n ϭ 3,964 visits, 7.3%), 5-17 years old (n ϭ 22,736 visits, 42.1%), 18 -59 years old (n ϭ 22,489 visits, 41.7%), and Ͼ60 years old (n ϭ 719 visits, 1.3%). Age information was unavailable for 4,038 visits (7.5%). Table 1 compares the reported health visit utilization of neurologic disease, standardized by number of reporting months available.
DISCUSSION
The UNHCR webHIS demonstrates feasibility of an active reporting system for key neurologic diseases in refugee camps on a global basis. WebHIS depends on the skills of nonphysician health care workers to report on neurologic diseases to monitor disease outbreaks, reveal health utilization trends, and develop broad estimates of the burden of disease. To date, most reported neurologic diseases of interest to UNHCR have been infectious in nature. However, these results suggest that infectious neurologic diseases are much less common than epilepsy and stroke.
The recent inclusion of stroke and epilepsy on reporting forms will be crucial for future humanitar- refugees in camps, including studies focusing on different age groups. It is not reported whether cases were treated or untreated. If, however, each health visit for epilepsy represented one individual who required antiepileptic drug treatment, the cost of phenobarbital to treat all refugees would be relatively small. Given a median defined daily dose of phenobarbital of 100 mg, the cost to treat all refugees with epilepsy in camps would be approximately $270,000 USD (estimated approximately $5 USD per person per year). Monitoring of meningitis in sub-Saharan Africa is an important way to avoid epidemic outbreaks due to Neisseria meningitidis. Although likely underreported here, the overall low counts of meningitis should be considered as a success of surveillance, treatment, and recent vaccination campaigns. In Goma, Democratic Republic of Congo (former Zaire) in 1994, recovery rates from meningococcal meningitis treated with IV penicillin and chloramphenicol in a field hospital were comparable to rates found in advanced medical facilities. 2 Early vaccination against meningococcal meningitis in a refugee camp of Sudanese nationals in northern Uganda led to less deaths compared to a camp where vaccination was delayed. 3 Simple, reliable surveillance systems for meningitis have been advocated for more than 20 years 4 ; however, even when implemented, important infectious disease outbreaks can be missed. The eventual inclusion of dementia, traumatic head and spinal cord injury, cerebral palsy, and chronic pain will also be important in the surveillance of neurologic diseases in future humanitarian crisis settings; this will require further training of medical staff on diagnosis and treatment.
We recognize important limitations to reporting data from the webHIS. Data are reported for each visit rather than for each refugee. The population structure of refugee camps is not static. Therefore, incidence and prevalence estimates of disease by country and camp level cannot be made. Data were entered based on standard case definitions and were not verified by physicians in many cases. Cases of meningitis were unlikely to have had routine CSF confirmation, and others may not have reached medical attention. Cerebral malaria and multiple other neurologic diseases of importance to refugees may not be reported because of a lack of training and limited monitoring of implementation of individual reporting categories. Therefore, it is assumed that there is significant under-reporting and risk of misclassification of most neurologic diseases.
However, given the available evidence, there is a growing need for guidelines for the prevention, evaluation, and care of refugees with neurologic diseases. This includes better coordination of information and action through roll-out programs for aspirin, antihypertensive medications, phenobarbital, phenytoin, analgesics, and potentially other antiepileptic drugs and levodopa. Since refugee camps often have better reporting capacity and treatment availability than for populations in the host country, attention to the neurologic health of refugees can advance care in the larger geographic regions where camps exist.
